Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Dec;36(12):2766–2773. doi: 10.1128/aac.36.12.2766

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.

B Brismar 1, A S Malmborg 1, G Tunevall 1, B Wretlind 1, L Bergman 1, L O Mentzing 1, P O Nyström 1, E Kihlström 1, B Bäckstrand 1, T Skau 1, et al.
PMCID: PMC245542  PMID: 1336347

Abstract

In order to compare the clinical and microbiological efficacies and safety of piperacillin plus tazobactam with those of imipenem plus cilastatin, 134 patients with intra-abdominal infections (73 patients with appendicitis) participated in an open randomized comparative multicenter trial. A total of 40 men and 29 women (mean age, 53 years; age range, 18 to 92 years) were enrolled in the piperacillin-tazobactam group and 40 men and 25 women (mean age, 54 years; age range, 16 to 91 years) were enrolled in the imipenem-cilastatin group. The patients received either piperacillin (4 g) and tazobactam (500 mg) every 8 h or imipenem and cilastatin (500 mg each) every 8 h. Both regimens were given by intravenous infusion. A total of 113 patients were clinically evaluable. Of 55 patients who received piperacillin-tazobactam, 50 were clinically cured, while 40 of 58 patients in the imipenem-cilastatin group were clinically cured. The differences were significant (Wilcoxon test; P = 0.005). There were 4 failures or relapses in the piperacillin-tazobactam group and 18 failures or relapses in the imipenem-cilastatin group. The microorganisms isolated were eradicated in similar proportions in the two patient groups. Adverse reactions, mainly gastrointestinal disturbances and nausea, were noted in 13 patients who received piperacillin-tazobactam and in 14 patients who received imipenem-cilastatin. Results of the present study show that piperacillin-tazobactam is effective and safe for the treatment of intra-abdominal infections.

Full text

PDF
2771

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff S. C., Jacobs M. R., Johenning S., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother. 1984 Oct;26(4):580–582. doi: 10.1128/aac.26.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fink M. P., Helsmoortel C. M., Arous E. J., Doern G. V., Moriarty K. P., Fairchild P. G., Townsend P. L. Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/gentamicin in serious intra-abdominal infections. J Antimicrob Chemother. 1989 Nov;24 (Suppl B):147–156. doi: 10.1093/jac/24.suppl_b.147. [DOI] [PubMed] [Google Scholar]
  3. Fortner C. L., Finley R. S., Schimpff S. C. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy. 1982 Nov-Dec;2(6):287–299. doi: 10.1002/j.1875-9114.1982.tb03202.x. [DOI] [PubMed] [Google Scholar]
  4. Gonzenbach H. R., Simmen H. P., Amgwerd R. Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections. Ann Surg. 1987 Mar;205(3):271–275. doi: 10.1097/00000658-198703000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gutmann L., Kitzis M. D., Yamabe S., Acar J. F. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother. 1986 May;29(5):955–957. doi: 10.1128/aac.29.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hackford A. W., Tally F. P., Reinhold R. B., Barza M., Gorbach S. L. Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections. Arch Surg. 1988 Mar;123(3):322–326. doi: 10.1001/archsurg.1988.01400270056008. [DOI] [PubMed] [Google Scholar]
  7. Jacobs M. R., Aronoff S. C., Johenning S., Shlaes D. M., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1986 Jun;29(6):980–985. doi: 10.1128/aac.29.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jauregui L. E., Appelbaum P. C., Fabian T. C., Hageage G., Strausbaugh L., Martin L. F. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1990 Mar;25(3):423–433. doi: 10.1093/jac/25.3.423. [DOI] [PubMed] [Google Scholar]
  9. Kager L., Nord C. E. Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience. Rev Infect Dis. 1985 Jul-Aug;7 (Suppl 3):S518–S521. doi: 10.1093/clinids/7.supplement_3.s518. [DOI] [PubMed] [Google Scholar]
  10. Solomkin J. S., Dellinger E. P., Christou N. V., Busuttil R. W. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg. 1990 Nov;212(5):581–591. doi: 10.1097/00000658-199011000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Solomkin J. S., Fant W. K., Rivera J. O., Alexander J. W. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med. 1985 Jun 7;78(6A):85–91. doi: 10.1016/0002-9343(85)90106-8. [DOI] [PubMed] [Google Scholar]
  12. Wang C., Pappas F., Cook T. Imipenem/cilastatin: a multicentre international study of its clinical efficacy, safety and potential as empirical therapy. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):185–191. doi: 10.1093/jac/18.supplement_e.185. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES